Soleno Reports $190.4M VYKAT XR Sales, $20.9M Net Income in 2025
Soleno generated net revenue of $91.7M in Q4 and $190.4M full-year from VYKAT XR, achieving $20.9M net income and $48.7M operating cash flow, with 1,250 patient starts and 859 active patients by year-end. The company ended 2025 with $506.1M cash, committed $100M to accelerated share repurchase, and reported 630 prescribers covering over 185M lives, while pursuing EU approval and additional rare disease indications.
1. Financial Results and Profitability
Soleno reported product net revenue of $91.7 million in Q4 and $190.4 million for full-year 2025, compared with no sales in 2024, translating into a positive net income of $20.9 million and $48.7 million of operating cash flow in the fourth quarter.
2. Commercial Launch Metrics
Since FDA approval on March 26, 2025, Soleno has received 1,250 patient start forms (207 in Q4), engaged 630 unique prescribers (136 added in Q4), and has 859 active patients on VYKAT XR, with coverage extending to more than 185 million lives in the U.S.
3. Cash Position and Future Strategy
The company invested $100 million in an accelerated share repurchase program and closed the year with $506.1 million in cash, cash equivalents and marketable securities. Soleno plans to pursue regulatory approval in the EU and evaluate its diazoxide choline extended-release therapy in additional rare disease indications.